The current status of blood epigenetic biomarkers for dementia

References

• Patterson C, World Alzheimer Report 2018. Alzheimer’s Disease International (ADI), London. 2018.
   Google Scholar
• Hugo J, Ganguli M. Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med. 2014;30:421–442.
   PubMed Web of Science ®Google Scholar
• Chertkow H, Feldman HH, Jacova C, et al. Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. Alzheimer's Res Ther. 2013;5:S2.
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–944.
   PubMed Web of Science ®Google Scholar
• Trivedi D. Cochrane Review Summary: Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Prim Health Care Res Dev. 2017;18:527–528.
   PubMed Web of Science ®Google Scholar
• Cullen B, O'Neill B, Evans JJ, et al. A review of screening tests for cognitive impairment. J Neurol Neurosurg Psychiatr. 2007;78:790–799.
   PubMed Web of Science ®Google Scholar
• Health Quality Ontario. The appropriate use of neuroimaging in the diagnostic work-up of dementia: an evidence-based analysis. Ont Health Technol Assess Ser. 2014;14(1):1–64.
   Google Scholar
• Harper L, Fumagalli GG, Barkhof F, et al. MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain. 2016;139:1211–1225.
   PubMed Web of Science ®Google Scholar
• Chrisp TAC, Thomas BD, Goddard WA, et al. Dementia timeline: journeys, delays and decisions on the pathway to an early diagnosis. Dementia. 2011;10:555–570.
   Google Scholar
• Ryan J, Fransquet P, Wrigglesworth J, et al. Phenotypic heterogeneity in dementia: a challenge for epidemiology and biomarker studies. Front Public Health. 2018;6:181
   PubMed Web of Science ®Google Scholar
• Cunningham EL, McGuinness B, Herron B, et al. Dementia. Ulster Med J. 2015;84:79–87.
   PubMedGoogle Scholar
• Gao FB, Almeida S, Lopez-Gonzalez R. Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. EMBO J. 2017;36:2931–2950.
   PubMed Web of Science ®Google Scholar
• Strimbu K, Tavel JA. What are biomarkers? Curr Opin Hiv Aids. 2010;5:463–466.
   PubMed Web of Science ®Google Scholar
• Mythili S, Malathi N. Diagnostic markers of acute myocardial infarction. Biomed Rep. 2015;3:743–748.
   PubMed Web of Science ®Google Scholar
• Dorcely B, Katz K, Jagannathan R, et al. Novel biomarkers for prediabetes, diabetes, and associated complications. DMSO. 2017;10:345–361.
   Google Scholar
• Engelborghs S, Niemantsverdriet E, Struyfs H, et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's Dement. 2017;8:111–126.
   Google Scholar
• Ritchie C, Smailagic N, Noel-Storr AH, et al. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017;(3):CD010803.
   PubMedGoogle Scholar
• Niemantsverdriet E, Valckx S, Bjerke M, et al. Alzheimer's disease CSF biomarkers: clinical indications and rational use. Acta Neurol Belg. 2017;117:591–602.
   PubMed Web of Science ®Google Scholar
• Mounsey AL, Zeitler MR. Cerebrospinal fluid biomarkers for detection of alzheimer disease in patients with mild cognitive impairment. Am Fam Physician. 2018;97:714–715.
   PubMed Web of Science ®Google Scholar
• Ahmed SV, Jayawarna C, Jude E. Post lumbar puncture headache: diagnosis and management. Postgrad Med J. 2006;82:713–716.
   PubMed Web of Science ®Google Scholar
• Payoux P, Salabert AS. New PET markers for the diagnosis of dementia. Curr Opin Neurol. 2017;30:608–616.
   PubMed Web of Science ®Google Scholar
• Iaccarino L, Sala A, Caminiti SP, et al. The emerging role of PET imaging in dementia. F1000Res. 2017;6:1830.
   PubMedGoogle Scholar
• Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimer's Dement. 2013;9:e-1–16.
   PubMed Web of Science ®Google Scholar
• Dubois B, Hampel H, Feldman HH, et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 2016;12:292–323.
   PubMed Web of Science ®Google Scholar
• Hostetler ED, Walji AM, Zeng Z, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57:1599–1606.
   PubMed Web of Science ®Google Scholar
• Chételat G, La Joie R, Villain N, et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. NeuroImage Clin. 2013;2:356–365.
   PubMed Web of Science ®Google Scholar
• Brown RK, Bohnen NI, Wong KK, et al. Brain PET in suspected dementia: patterns of altered FDG metabolism. Radiographics. 2014;34:684–701.
   PubMed Web of Science ®Google Scholar
• Herholz K. Guidance for reading FDG PET scans in dementia patients. Q J Nucl Med Mol Imaging. 2014;58(4):332–343.
   PubMed Web of Science ®Google Scholar
• Scott KR, Barrett AM. Dementia syndromes: evaluation and treatment. Exp Rev Neurother. 2007;7:407–422.
   PubMedGoogle Scholar
• Londin ER, Keller MA, D'Andrea MR, et al. Whole-exome sequencing of DNA from peripheral blood mononuclear cells (PBMC) and EBV-transformed lymphocytes from the same donor. BMC Genomics. 2011;12:464–464.
   PubMed Web of Science ®Google Scholar
• Terry MB, Delgado-Cruzata L, Vin-Raviv N, et al. DNA methylation in white blood cells: association with risk factors in epidemiologic studies. Epigenetics. 2011;6:828–837.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang X, Lu X, et al. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. Cell Res. 2017;27:1243–1257.
   PubMed Web of Science ®Google Scholar
• Chen S-H, Bu X-L, Jin W-S, et al. Altered peripheral profile of blood cells in Alzheimer disease: a hospital-based case-control study. Medicine. 2017;96:e6843–e6843.
   PubMed Web of Science ®Google Scholar
• Claus M, Dychus N, Ebel M, et al. Measuring the immune system: a comprehensive approach for the analysis of immune functions in humans. Arch Toxicol. 2016;90:2481–2495.
   PubMed Web of Science ®Google Scholar
• Wu J, Li L. Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications. J Biomed Res. 2016;30:361–372.
   PubMed Web of Science ®Google Scholar
• Couderc R, Antar M, Bonnefont-Rousselot D, et al. Blood lipid tests in 2017. Ann Biol Clin. 2017;75:646–652.
   PubMed Web of Science ®Google Scholar
• Rahaghi FN, Gough DA. Blood glucose dynamics. Diabetes Technol Ther. 2008;10:81–94.
   PubMed Web of Science ®Google Scholar
• Nissum M, Foucher AL. Analysis of human plasma proteins: a focus on sample collection and separation using free-flow electrophoresis. Expert Rev Proteomics. 2008;5:571–587.
   PubMed Web of Science ®Google Scholar
• Prabhakar NR, Semenza GL. Oxygen sensing and homeostasis. Physiology. 2015;30:340–348.
   PubMed Web of Science ®Google Scholar
• Peters TL, Beard JD, Umbach DM, et al. Blood levels of trace metals and amyotrophic lateral sclerosis. Neurotoxicology. 2016;54:119–126.
   PubMed Web of Science ®Google Scholar
• Menéndez-González M. Routine lumbar puncture for the early diagnosis of Alzheimer's disease. Is it safe? Front Aging Neurosci. 2014;6:65.
   PubMed Web of Science ®Google Scholar
• Arbor SC, LaFontaine M, Cumbay M. Amyloid-beta Alzheimer targets — protein processing, lipid rafts, and amyloid-beta pores. Yale J Biol Med. 2016;89:5–21.
   PubMedGoogle Scholar
• Okamura N, Harada R, Furumoto S, et al. Tau PET imaging in Alzheimer's disease. Curr Neurol Neurosci Rep. 2014;14:500.
   PubMed Web of Science ®Google Scholar
• Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673–684.
   PubMed Web of Science ®Google Scholar
• Chen Z, Mengel D, Keshavan A, et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. Alzheimers Dement. 2018;15(3):487–496.
   PubMed Web of Science ®Google Scholar
• Lue LF, Guerra A, Walker DG. Amyloid beta and tau as Alzheimer's disease blood biomarkers: promise from new technologies. Neurol Ther. 2017;6:25–36.
   PubMed Web of Science ®Google Scholar
• Blennow K. A review of fluid biomarkers for Alzheimer's disease: moving from CSF to blood. Neurol Ther. 2017;6:15–24.
   PubMed Web of Science ®Google Scholar
• Yang SY, Chiu MJ, Chen TF, et al. Detection of plasma biomarkers using immunomagnetic reduction: a promising method for the early diagnosis of Alzheimer's disease. Neurol Ther. 2017;6:37–56.
   PubMed Web of Science ®Google Scholar
• Liu TC, Lee YC, Ko CY, et al. Highly sensitive/selective 3D nanostructured immunoparticle-based interface on a multichannel sensor array for detecting amyloid-beta in Alzheimer's disease. Theranostics. 2018;8:4210–4225.
   PubMed Web of Science ®Google Scholar
• Sun L, Zhong Y, Gui J, et al. A hydrogel biosensor for high selective and sensitive detection of amyloid-beta oligomers. Int J Nanomedicine. 2018;13:843–856.
   PubMed Web of Science ®Google Scholar
• Kim H, Lee JU, Song S, et al. A shape-code nanoplasmonic biosensor for multiplex detection of Alzheimer's disease biomarkers. Biosens Bioelectron. 2018;101:96–102.
   PubMed Web of Science ®Google Scholar
• Shen L, Liao L, Chen C, et al. Proteomics analysis of blood serums from Alzheimer's disease patients using iTRAQ labeling technology. J Alzheimers Dis. 2017;56:361–378.
   PubMed Web of Science ®Google Scholar
• An SSA, Lee BS, Yu JS, et al. Dynamic changes of oligomeric amyloid beta levels in plasma induced by spiked synthetic Abeta42. Alzheimers Res Ther. 2017;9:86.
   PubMed Web of Science ®Google Scholar
• Gupta VB, Hone E, Pedrini S, et al. Altered levels of blood proteins in Alzheimer's disease longitudinal study: results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. Alzheimers Dement. 2017;8:60–72.
   Google Scholar
• Hsu JL, Lee WJ, Liao YC, et al. The clinical significance of plasma clusterin and Abeta in the longitudinal follow-up of patients with Alzheimer's disease. Alzheimers Res Ther. 2017;9:91.
   PubMed Web of Science ®Google Scholar
• D'Anna L, Abu-Rumeileh S, Fabris M, et al. Serum interleukin-10 levels correlate with cerebrospinal fluid amyloid beta deposition in Alzheimer disease patients. Neurodegener Dis. 2017;17:227–234.
   PubMed Web of Science ®Google Scholar
• Villarreal AE, O'Bryant SE, Edwards M, et al. Serum-based protein profiles of Alzheimer's disease and mild cognitive impairment in elderly Hispanics. Neurodegener Dis Manage. 2016;6:203–213.
   PubMed Web of Science ®Google Scholar
• Mohd Hasni DS, Lim SM, Chin AV, et al. Peripheral cytokines, C-X-C motif ligand10 and interleukin-13, are associated with Malaysian Alzheimer's disease. Geriatr Gerontol Int. 2017;17:839–846.
   PubMed Web of Science ®Google Scholar
• Hesse R, Wahler A, Gummert P, et al. Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1beta. BMC Neurol. 2016;16:185.
   PubMed Web of Science ®Google Scholar
• Shen XN, Niu LD, Wang YJ, et al. Inflammatory markers in Alzheimer's disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. J Neurol Neurosurg Psychiatry. 2019;90:590–598.
   PubMed Web of Science ®Google Scholar
• Lauriola M, Paroni G, Ciccone F, et al. Erythrocyte associated amyloid-beta as potential biomarker to diagnose dementia. Curr Alzheimer Res. 2018;15:381–385.
   PubMed Web of Science ®Google Scholar
• Goozee K, Chatterjee P, James I, et al. Alterations in erythrocyte fatty acid composition in preclinical Alzheimer's disease. Sci Rep. 2017;7:676.
   PubMed Web of Science ®Google Scholar
• Defrancesco M, Marksteiner J, Humpel C. Reduced beta-amyloid sensitivity for platelet-monocyte aggregates in EDTA blood of alzheimer patients. Int Psychogeriatr. 2018;30:147–152.
   PubMed Web of Science ®Google Scholar
• Tramutola A, Abate G, Lanzillotta C, et al. Protein nitration profile of CD3(+) lymphocytes from Alzheimer disease patients: novel hints on immunosenescence and biomarker detection. Free Radic Biol Med. 2018;129:430–439.
   PubMed Web of Science ®Google Scholar
• Balietti M, Giuli C, Conti F. Peripheral blood brain-derived neurotrophic factor as a biomarker of Alzheimer's disease: are there methodological biases? Mol Neurobiol. 2018;55:6661–6672.
   PubMed Web of Science ®Google Scholar
• Wang R, Chen Z, Fu Y, et al. Plasma cystatin C and high-density lipoprotein are important biomarkers of Alzheimer's disease and vascular dementia: a cross-sectional study. Front Aging Neurosci. 2017;9:26.
   PubMed Web of Science ®Google Scholar
• Han SH, Park JC, Byun MS, et al. Blood acetylcholinesterase level is a potential biomarker for the early detection of cerebral amyloid deposition in cognitively normal individuals. Neurobiol Aging. 2019;73:21–29.
   PubMed Web of Science ®Google Scholar
• Varma VR, Varma S, An Y, et al. Alpha-2 macroglobulin in Alzheimer's disease: a marker of neuronal injury through the RCAN1 pathway. Mol Psychiatry. 2017;22:13–23.
   PubMed Web of Science ®Google Scholar
• Toledo JB, Arnold M, Kastenmuller G, et al. Metabolic network failures in Alzheimer's disease: a biochemical road map. Alzheimers Dement. 2017;13:965–984.
   PubMed Web of Science ®Google Scholar
• Siotto M, Simonelli I, Pasqualetti P, et al. Association between serum ceruloplasmin specific activity and risk of Alzheimer's disease. J Alzheimers Dis. 2016;50:1181–1189.
   PubMed Web of Science ®Google Scholar
• Hare DJ, Doecke JD, Faux NG, et al. Decreased plasma iron in Alzheimer's disease is due to transferrin desaturation. ACS Chem Neurosci. 2015;6:398–402.
   PubMed Web of Science ®Google Scholar
• Zhou W, Zhang J, Ye F, et al. Plasma neurofilament light chain levels in Alzheimer's disease. Neurosci Lett. 2017;650:60–64.
   PubMed Web of Science ®Google Scholar
• Ashton NJ, Leuzy A, Lim YM, et al. Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Commun. 2019;7:5.
   PubMed Web of Science ®Google Scholar
• Preische O, Schultz SA, Apel A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019;25:277.
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Ermann N, Andreasson U, et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. Alz Res Therapy. 2018;10:71.
   PubMed Web of Science ®Google Scholar
• Moosavi A, Motevalizadeh Ardekani A. Role of epigenetics in biology and human diseases. Iran Biomed J. 2016;20:246–258.
   PubMedGoogle Scholar
• Huang K, Fan G. DNA methylation in cell differentiation and reprogramming: an emerging systematic view. Regen Med. 2010;5:531–544.
   PubMed Web of Science ®Google Scholar
• Wu W. MicroRNA sequencing data analysis toolkits. Methods Mol Biol. 2018;1699:211–215.
   PubMedGoogle Scholar
• Miao F, Wu X, Zhang L, et al. Histone methylation patterns are cell-type specific in human monocytes and lymphocytes and well maintained at core genes. J Immunol. 2008;180:2264–2269.
   PubMed Web of Science ®Google Scholar
• Dmitrijeva M, Schaefer MH, Ossowski S, et al. Tissue-specific DNA methylation loss during ageing and carcinogenesis is linked to chromosome structure, replication timing and cell division rates. Nucleic Acids Res. 2018;46:7022–7039.
   PubMed Web of Science ®Google Scholar
• Biamonte F, Zolea F, Santamaria G, et al. Human haematological and epithelial tumor-derived cell lines express distinct patterns of onco-microRNAs. Cell Mol Biol (Noisy-le-Grand). 2017;63:75–85.
   PubMed Web of Science ®Google Scholar
• Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012;13:343–357.
   PubMed Web of Science ®Google Scholar
• Klein H-U, Bennett DA, De Jager PL. The epigenome in Alzheimer's disease: current state and approaches for a new path to gene discovery and understanding disease mechanism. Acta Neuropathol. 2016;132:503–514.
   PubMed Web of Science ®Google Scholar
• Fransquet PD, Lacaze P, Saffery R, et al. Blood DNA methylation as a potential biomarker of dementia: a systematic review. Alzheimers Dement. 2017;14:81–103.
   PubMed Web of Science ®Google Scholar
• Fransquet PD, Ryan J. Micro RNA as a potential blood-based epigenetic biomarker for Alzheimer's disease. Clin Biochem. 2018;58:5–14.
   PubMed Web of Science ®Google Scholar
• Auclair G, Weber M. Mechanisms of DNA methylation and demethylation in mammals. Biochimie. 2012;94:2202–2211.
   PubMed Web of Science ®Google Scholar
• Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacol. 2013;38:23–38.
   PubMed Web of Science ®Google Scholar
• De Jager PL, Srivastava G, Lunnon K, et al. Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat Neurosci. 2014;17:1156–1163.
   PubMed Web of Science ®Google Scholar
• Bradburn S, McPhee J, Bagley L, et al. Dysregulation of C-X-C motif ligand 10 during aging and association with cognitive performance. Neurobiol Aging. 2018;63:54–64.
   PubMed Web of Science ®Google Scholar
• Chen W, Zhou X, Duan Y, et al. Association of OGG1 and DLST promoter methylation with Alzheimer's disease in Xinjiang population. Exp Ther Med. 2018;16:3135–3142.
   PubMed Web of Science ®Google Scholar
• Cooper YA, Nachun D, Dokuru D, et al. Progranulin levels in blood in Alzheimer's disease and mild cognitive impairment. Ann Clin Transl Neurol. 2018;5:616–629.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhao W, Ware EB, et al. DNA methylation in the APOE genomic region is associated with cognitive function in African Americans. BMC Med Genomics. 2018;11:43.
   PubMed Web of Science ®Google Scholar
• Madrid A, Hogan KJ, Papale LA, et al. DNA hypomethylation in blood links B3GALT4 and ZADH2 to Alzheimer's disease. J Alzheimers Dis. 2018;66:927–934.
   PubMed Web of Science ®Google Scholar
• Marioni RE, McRae AF, Bressler J, et al. Meta-analysis of epigenome-wide association studies of cognitive abilities. Mol Psychiatry. 2018;23:2133–2144.
   PubMed Web of Science ®Google Scholar
• Mercorio R, Pergoli L, Galimberti D, et al. PICALM gene methylation in blood of Alzheimer's disease patients is associated with cognitive decline. J Alzheimers Dis. 2018;65:283–292.
   PubMed Web of Science ®Google Scholar
• Sao T, Yoshino Y, Yamazaki K, et al. MEF2C mRNA expression and cognitive function in Japanese patients with Alzheimer's disease. Psychiatry Clin Neurosci. 2018;72:160–167.
   PubMed Web of Science ®Google Scholar
• Shao Y, Shaw M, Todd K, et al. DNA methylation of TOMM40-APOE-APOC2 in Alzheimer's disease. J Hum Genet. 2018;63:459–471.
   PubMed Web of Science ®Google Scholar
• Verschoor CP, McEwen LM, Kobor MS, et al. DNA methylation patterns are related to co-morbidity status and circulating C-reactive protein levels in the nursing home elderly. Exper Gerontol. 2018;105:47–52.
   PubMed Web of Science ®Google Scholar
• Wezyk M, Spolnicka M, Pospiech E, et al. Hypermethylation of TRIM59 and KLF14 influences cell death signaling in familial Alzheimer's disease. Oxid Med Cell Longev. 2018;2018:6918797.
   PubMedGoogle Scholar
• Xu C, Liu G, Ji H, et al. Elevated methylation of OPRM1 and OPRL1 genes in Alzheimer's disease. Mol Med Report. 2018;18:4297–4302.
   PubMed Web of Science ®Google Scholar
• Yoshino Y, Funahashi Y, Nakata S, et al. Ghrelin cascade changes in the peripheral blood of Japanese patients with Alzheimer's disease. J Psychiatr Res. 2018;107:79–85.
   PubMed Web of Science ®Google Scholar
• Boden KA, Barber IS, Clement N, et al. Methylation profiling RIN3 and MEF2C identifies epigenetic marks associated with sporadic early onset Alzheimer's disease. J Alzheimer Dis Rep. 2017;1:97–108.
   PubMedGoogle Scholar
• Funahashi Y, Yoshino Y, Yamazaki K, et al. DNA methylation changes at SNCA intron 1 in patients with dementia with Lewy bodies. Psychiatry Clin Neurosci. 2017;71:28–35.
   PubMed Web of Science ®Google Scholar
• Karimi M, Vedin I, Levi YF, et al. DHA-rich n-3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegAD study. Am J Clin Nutr. 2017;106:1157–1165.
   PubMed Web of Science ®Google Scholar
• Liu G, Ji H, Liu J, et al. Association of OPRK1 and OPRM1 methylation with mild cognitive impirment in Xinjiang Han and Uygur populations. Neurosci Lett. 2017;636:170–176.
   PubMed Web of Science ®Google Scholar
• Mise A, Yoshino Y, Yamazaki K, et al. TOMM40 and APOE gene expression and cognitive decline in Japanese Alzheimer's disease subjects. J Alzheimer Dis. 2017;60:1107–1117.
   PubMed Web of Science ®Google Scholar
• Ozaki Y, Yoshino Y, Yamazaki K, et al. DNA methylation changes at TREM2 intron 1 and TREM2 mRNA expression in patients with Alzheimer's disease. J Psychiatr Res. 2017;92:74–80.
   PubMed Web of Science ®Google Scholar
• Raina A, Zhao X, Grove ML, et al. Cerebral white matter hyperintensities on MRI and acceleration of epigenetic aging: the atherosclerosis risk in communities study. Clin Epigenet. 2017;9:21.
   PubMed Web of Science ®Google Scholar
• Sliwinska A, Sitarek P, Toma M, et al. Decreased expression level of BER genes in Alzheimer's disease patients is not derivative of their DNA methylation status. Prog Neuropsychopharmacol Biol Psychiatry. 2017;79:311–316.
   PubMed Web of Science ®Google Scholar
• Starnawska A, Tan Q, McGue M, et al. Epigenome-wide association study of cognitive functioning in middle-aged monozygotic twins. Front Aging Neurosci. 2017;9:413.
   PubMed Web of Science ®Google Scholar
• Stoccoro A, Siciliano G, Migliore L, et al. Decreased methylation of the mitochondrial D-loop region in late-onset Alzheimer's disease. J Alzheimers Dis. 2017;59:559–564.
   PubMed Web of Science ®Google Scholar
• Xie B, Xu Y, Liu Z, et al. Elevation of peripheral BDNF promoter methylation predicts conversion from amnestic mild cognitive impairment to Alzheimer's disease: a 5-year longitudinal study. J Alzheimers Dis. 2017;56:391–401.
   PubMed Web of Science ®Google Scholar
• Yoshino Y, Yamazaki K, Ozaki Y, et al. INPP5D mRNA expression and cognitive decline in Japanese Alzheimer's disease subjects. J Alzheimers Dis. 2017;58:687–694.
   PubMed Web of Science ®Google Scholar
• Zhang M, Tartaglia MC, Moreno D, et al. DNA methylation age-acceleration is associated with disease duration and age at onset in C9orf72 patients. Acta Neuropathol. 2017;134:271–279.
   PubMed Web of Science ®Google Scholar
• Horvath S, Garagnani P, Bacalini MG, et al. Accelerated epigenetic aging in Down syndrome. Aging Cell. 2015;14:491–495.
   PubMed Web of Science ®Google Scholar
• Lazarus J, Mather KA, Armstrong NJ, et al. DNA methylation in the apolipoprotein-A1 gene is associated with episodic memory performance in healthy older individuals. J Alzheimers Dis. 2015;44:175–182.
   PubMed Web of Science ®Google Scholar
• Lunnon K, Smith RG, Cooper I, et al. Blood methylomic signatures of presymptomatic dementia in elderly subjects with type 2 diabetes mellitus. Neurobiol Aging. 2015;36:1600.e1–1600.e4.
   Web of Science ®Google Scholar
• Basavaraju M, de Lencastre A. Alzheimer's disease: presence and role of microRNAs. Biomol Concepts. 2016;7:241–252.
   PubMedGoogle Scholar
• O'Brien J, Hayder H, Zayed Y, et al. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol. 2018;9:402–402.
   PubMed Web of Science ®Google Scholar
• Nelson PT, Wang WX. MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study. J Alzheimers Dis. 2010;21:75–79.
   PubMed Web of Science ®Google Scholar
• Wang WX, Rajeev BW, Stromberg AJ, et al. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci. 2008;28:1213–1223.
   PubMed Web of Science ®Google Scholar
• Caggiu E, Paulus K, Mameli G, et al. Differential expression of miRNA 155 and miRNA 146a in Parkinson's disease patients. eNeurologicalSci. 2018;13:1–4.
   PubMedGoogle Scholar
• Denk J, Oberhauser F, Kornhuber J, et al. Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. PLoS One. 2018;13:e0197329.
   PubMed Web of Science ®Google Scholar
• Kumar S, Reddy PH. MicroRNA-455-3p as a potential biomarker for Alzheimer's disease: an update. Front Aging Neurosci. 2018;10:41.
   PubMed Web of Science ®Google Scholar
• Kume K, Iwama H, Deguchi K, et al. Serum microRNA expression profiling in patients with multiple system atrophy. Mol Med Report. 2018;17:852–860.
   PubMed Web of Science ®Google Scholar
• Piscopo P, Grasso M, Puopolo M, et al. Circulating miR-127-3p as a potential biomarker for differential diagnosis in frontotemporal dementia. J Alzheimers Dis. 2018;65:455–464.
   PubMed Web of Science ®Google Scholar
• Vrabec K, Bostjancic E, Koritnik B, et al. Differential expression of several miRNAs and the host genes AATK and DNM2 in leukocytes of sporadic ALS patients. Front Mol Neurosci. 2018;11:106.
   PubMed Web of Science ®Google Scholar
• Yang TT, Liu CG, Gao SC, et al. The serum exosome derived microRNA-135a, -193b, and -384 were potential Alzheimer's disease biomarkers. Biomed Environ Sci. 2018;31:87–96.
   PubMed Web of Science ®Google Scholar
• Cao XY, Lu JM, Zhao ZQ, et al. MicroRNA biomarkers of Parkinson's disease in serum exosome-like microvesicles. Neurosci Lett. 2017;644:94–99.
   PubMed Web of Science ®Google Scholar
• Cosin-Tomas M, Antonell A, Llado A, et al. Plasma miR-34a-5p and miR-545-3p as early biomarkers of Alzheimer's disease: potential and limitations. Mol Neurobiol. 2017;54:5550–5562.
   PubMed Web of Science ®Google Scholar
• Guo R, Fan G, Zhang J, et al. A 9-microRNA signature in serum serves as a noninvasive biomarker in early diagnosis of Alzheimer's disease. J Alzheimers Dis. 2017;60:1365–1377.
   PubMed Web of Science ®Google Scholar
• Hara N, Kikuchi M, Miyashita A, et al. Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer's disease. Acta Neuropathol Commun. 2017;5:10.
   PubMed Web of Science ®Google Scholar
• Kumar S, Vijayan M, Reddy PH. MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer's disease. Hum Mol Genet. 2017;26:3808–3822.
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Laskowska-Kaszub K, Debski KJ, et al. Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer's disease patients from non-demented subjects. Oncotarget. 2017;8:16122–16143.
   PubMedGoogle Scholar
• Pang X, Zhao Y, Wang J, et al. The bioinformatic analysis of the dysregulated genes and microRNAs in entorhinal cortex, hippocampus, and blood for Alzheimer's disease. BioMed Res Int. 2017;2017:1.
   Google Scholar
• Prabhakar P, Chandra SR, Christopher R. Circulating microRNAs as potential biomarkers for the identification of vascular dementia due to cerebral small vessel disease. Age Ageing. 2017;46:861–864.
   PubMed Web of Science ®Google Scholar
• Sheinerman KS, Toledo JB, Tsivinsky VG, et al. Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Alz Res Therapy. 2017;9:89.
   PubMed Web of Science ®Google Scholar
• Wu Y, Xu J, Cheng J, et al. Lower serum levels of miR-29c-3p and miR-19b-3p as biomarkers for Alzheimer's disease. Tohoku J Exp Med. 2017;242:129–136.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Zou L, Qian L, et al. Expression of microRNA-222 in serum of patients with Alzheimer's disease. Molecul Med Rep. 2017;16:5575–5579.
   PubMed Web of Science ®Google Scholar
• Asahchop EL, Akinwumi SM, Branton WG, et al. Plasma microRNA profiling predicts HIV-associated neurocognitive disorder. Aids. 2016;30:2021–2031.
   PubMed Web of Science ®Google Scholar
• Ding H, Huang Z, Chen M, et al. Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease. Parkinsonism Relat Disord. 2016;22:68–73.
   PubMed Web of Science ®Google Scholar
• Jia LH, Liu YN. Downregulated serum miR-223 servers as biomarker in Alzheimer's disease. Cell Biochem Funct. 2016;34:233.
   PubMed Web of Science ®Google Scholar
• Keller A, Backes C, Haas J, et al. Validating Alzheimer's disease micro RNAs using next-generation sequencing. Alzheimer's Dement. 2016;12:565–576.
   PubMed Web of Science ®Google Scholar
• Ren RJ, Zhang YF, Dammer EB, et al. Peripheral blood microRNA expression profiles in Alzheimer's disease: screening, validation, association with clinical phenotype and implications for molecular mechanism. Mol Neurobiol. 2016;53:5772–5781.
   PubMed Web of Science ®Google Scholar
• Yilmaz SG, Erdal ME, Ozge AA, et al. Can peripheral microRNA expression data serve as epigenomic (upstream) biomarkers of Alzheimer's disease? Omics. 2016;20:456–461.
   PubMed Web of Science ®Google Scholar
• Zirnheld AL, Shetty V, Chertkow H, et al. Distinguishing mild cognitive impairment from Alzheimer's disease by increased expression of key circulating microRNAs. Curr Neurobiol. 2016;7:38–50.
   Google Scholar
• Cheng L, Doecke JD, Sharples RA, et al. Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment. Mol Psychiatry. 2015;20:1188–1196.
   PubMed Web of Science ®Google Scholar
• Dong H, Li J, Huang L, et al. Serum microRNA profiles serve as novel biomarkers for the diagnosis of Alzheimer's disease. Disease Markers. 2015;2015:1.
   Google Scholar
• Lugli G, Cohen AM, Bennett DA, et al. Plasma exosomal miRNAs in persons with and without Alzheimer disease: altered expression and prospects for biomarkers. PLoS One. 2015;10:e0139233.
   PubMed Web of Science ®Google Scholar
• Satoh JI, Kino Y, Niida S. MicroRNA-Seq data analysis pipeline to identify blood biomarkers for Alzheimer's disease from public data. Biomark Insights. 2015;10:21–31.
   PubMed Web of Science ®Google Scholar
• Xie B, Zhou H, Zhang R, et al. Serum miR-206 and miR-132 as potential circulating biomarkers for mild cognitive impairment. J Alzheimers Dis. 2015;45:721–731.
   PubMed Web of Science ®Google Scholar
• Bhatnagar S, Chertkow H, Schipper HM, et al. Increased microRNA-34c abundance in Alzheimer's disease circulating blood plasma. Front Mol Neurosci. 2014;7:2.
   PubMed Web of Science ®Google Scholar
• De Felice B, Annunziata A, Fiorentino G, et al. miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients. Neurogenetics. 2014;15:243–253.
   PubMed Web of Science ®Google Scholar
• De Felice B, Mondola P, Sasso A, et al. Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-beta. BMC Med Genomics. 2014;7:26.
   PubMed Web of Science ®Google Scholar
• Galimberti D, Villa C, Fenoglio C, et al. Circulating miRNAs as potential biomarkers in Alzheimer's disease. J Alzheimers Dis. 2014;42:1261–1267.
   PubMed Web of Science ®Google Scholar
• Kiko T, Nakagawa K, Tsuduki T, et al. MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer's disease. J Alzheimers Dis. 2014;39:253–259.
   PubMed Web of Science ®Google Scholar
• Liu CG, Wang JL, Li L, et al. MicroRNA-135a and -200b, potential Biomarkers for Alzheimer's disease, regulate beta secretase and amyloid precursor protein. Brain Res. 2014;1583:55–64.
   PubMed Web of Science ®Google Scholar
• Liu CG, Song J, Zhang YQ, et al. MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer's disease. Mol Med Rep. 2014;10:2395–2400.
   PubMed Web of Science ®Google Scholar
• Liu CG, Wang JL, Li L, et al. MicroRNA-384 regulates both amyloid precursor protein and beta-secretase expression and is a potential biomarker for Alzheimer's disease. Int J Mol Med. 2014;34:160–166.
   PubMed Web of Science ®Google Scholar
• Tan L, Yu JT, Liu QY, et al. Circulating miR-125b as a biomarker of Alzheimer's disease. J Neurol Sci. 2014;336:52–56.
   PubMed Web of Science ®Google Scholar
• Tan L, Yu JT, Tan MS, et al. Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease. J Alzheimers Dis. 2014;40:1017–1027.
   PubMed Web of Science ®Google Scholar
• Bekris LM, Lutz F, Montine TJ, et al. MicroRNA in Alzheimer's disease: an exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers. 2013;18:455–466.
   PubMed Web of Science ®Google Scholar
• Leidinger P, Backes C, Deutscher S, et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 2013;14:R78.
   PubMed Web of Science ®Google Scholar
• Sheinerman KS, Tsivinsky VG, Abdullah L, et al. Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study. Aging. 2013;5:925–938.
   PubMedGoogle Scholar
• Geekiyanage H, Jicha GA, Nelson PT, et al. Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease. Exp Neurol. 2012;235:491–496.
   PubMed Web of Science ®Google Scholar
• Sheinerman KS, Tsivinsky VG, Crawford F, et al. Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging. 2012;4:590–605.
   PubMedGoogle Scholar
• Talbert PB, Ahmad K, Almouzni G, et al. A unified phylogeny-based nomenclature for histone variants. Epigenet Chromatin. 2012;5:7.
   PubMed Web of Science ®Google Scholar
• Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol. 2004;14:R546–R551.
   PubMed Web of Science ®Google Scholar
• Janssen KA, Sidoli S, Garcia BA. Recent achievements in characterizing the histone code and approaches to integrating epigenomics and systems biology. Methods Enzymol. 2017;586:359–378.
   PubMed Web of Science ®Google Scholar
• Drake J, Petroze R, Castegna A, et al. 4-Hydroxynonenal oxidatively modifies histones: implications for Alzheimer's disease. Neurosci Lett. 2004;356:155–158.
   PubMed Web of Science ®Google Scholar
• Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21:381–395.
   PubMed Web of Science ®Google Scholar
• Griffiths-Jones S, Grocock RJ, van DS, et al. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006;;34:D140–D144.
   PubMed Web of Science ®Google Scholar
• Saffery R, Gordon L. Time for a standardized system of reporting sites of genomic methylation. Genome Biol. 2015;16:85.
   PubMed Web of Science ®Google Scholar
• Pidsley R, Zotenko E, Peters TJ, et al. Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. Genome Biol. 2016;17:208.
   PubMed Web of Science ®Google Scholar
• Plagg B, Ehrlich D, Kniewallner KM, et al. Increased acetylation of histone H4 at lysine 12 (H4K12) in monocytes of transgenic Alzheimer's mice and in human patients. Curr Alzheimer Res. 2015;12:752–760.
   PubMed Web of Science ®Google Scholar
• Kim J, Kim H. Recruitment and biological consequences of histone modification of H3K27me3 and H3K9me3. ILAR J. 2012;53:232–239.
   PubMed Web of Science ®Google Scholar
• Kim J, Lee S, Choi BR, et al. Sulforaphane epigenetically enhances neuronal BDNF expression and TrkB signaling pathways. Mol Nutr Food Res. 2017;61. DOI:10.1002/mnfr.201600194
   Web of Science ®Google Scholar
• Yamakawa H, Cheng J, Penney J, et al. The transcription factor Sp3 cooperates with HDAC2 to regulate synaptic function and plasticity in neurons. Cell Rep. 2017;20:1319–1334.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Zuniga M, Contreras PS, Estrada LD, et al. c-Abl stabilizes HDAC2 levels by tyrosine phosphorylation repressing neuronal gene expression in Alzheimer's disease. Mol Cell. 2014;56:163–173.
   PubMed Web of Science ®Google Scholar
• Wang BY, Zhong Y, Zhao Z, et al. Epigenetic suppression of hippocampal BDNF mediates the memory deficiency induced by amyloid fibrils. Pharmacol Biochem Behav. 2014;126:83–89.
   PubMed Web of Science ®Google Scholar
• Janczura KJ, Volmar CH, Sartor GC, et al. Inhibition of HDAC3 reverses Alzheimer's disease-related pathologies in vitro and in the 3xTg-AD mouse model. Proc Natl Acad Sci USA. 2018;115:E11148–E11157.
   PubMed Web of Science ®Google Scholar
• Igarashi S, Morita H, Bennett KM, et al. Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. Neuroreport. 2003;14:565–568.
   PubMed Web of Science ®Google Scholar
• Wood IC. The contribution and therapeutic potential of epigenetic modifications in Alzheimer's disease. Front Neurosci. 2018;12:649.
   PubMed Web of Science ®Google Scholar
• She A, Kurtser I, Reis SA, et al. Selectivity and kinetic requirements of HDAC inhibitors as progranulin enhancers for treating frontotemporal dementia. Cell Chem Biol. 2017;24:892–906.e5.
   PubMed Web of Science ®Google Scholar
• Sanchez-Arias JA, Rabal O, Cuadrado-Tejedor M, et al. Impact of scaffold exploration on novel dual-acting histone deacetylases and phosphodiesterase 5 inhibitors for the treatment of Alzheimer's disease. ACS Chem Neurosci 2017;8:638–661.
   PubMed Web of Science ®Google Scholar
• Sadri-Vakili G, Cha JH. Mechanisms of disease: histone modifications in Huntington's disease. Nat Rev Neurol. 2006;2:330–338.
   Google Scholar
• Sadri-Vakili G, Cha JH. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death). Curr Alzheimer Res. 2006;3:403–408.
   PubMedGoogle Scholar
• Li X, Bao X, Wang R. Neurogenesis-based epigenetic therapeutics for Alzheimer's disease (Review). Mol Med Rep. 2016;14:1043–1053.
   PubMed Web of Science ®Google Scholar
• Ganai SA, Banday S, Farooq Z, et al. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: a promising therapeutic strategy for neurological disorders. Pharmacol Ther. 2016;166:106–122.
   PubMed Web of Science ®Google Scholar
• Borovecki F, Lovrecic L, Zhou J, et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci USA. 2005;102:11023–11028.
   PubMed Web of Science ®Google Scholar
• Hu Y, Chopra V, Chopra R, et al. Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci USA. 2011;108:17141–17146.
   PubMed Web of Science ®Google Scholar
• Belzil VV, Bauer PO, Prudencio M, et al. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol. 2013;126:895–905.
   PubMed Web of Science ®Google Scholar
• Hampel H, O’Bryant SE, Molinuevo JL, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol. 2018;14:639–652.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Biomarker Qualification: Evidentiary Framework Guidance for Industry and FDA Staff (Draft). 2018.
   Google Scholar
• Sapkota S, Huan T, Tran T, et al. Alzheimer's biomarkers from multiple modalities selectively discriminate clinical status: relative importance of salivary metabolomics panels, genetic, lifestyle, cognitive, functional health and demographic risk markers. Front Aging Neurosci. 2018;10:296.
   PubMed Web of Science ®Google Scholar
• Sehgal V, Seviour EG, Moss TJ, et al. Robust selection algorithm (RSA) for multi-omic biomarker discovery; integration with functional network analysis to identify miRNA regulated pathways in multiple cancers. PLoS One. 2015;10:e0140072.
   PubMed Web of Science ®Google Scholar
• Abeel T, Helleputte T, Van de Peer Y, et al. Robust biomarker identification for cancer diagnosis with ensemble feature selection methods. Bioinformatics. 2010;26:392–398.
   PubMed Web of Science ®Google Scholar
• Eldridge RC, Flanders WD, Bostick RM, et al. Using multiple biomarkers and determinants to obtain a better measurement of oxidative stress: a latent variable structural equation model approach. Biomarkers. 2017;22:517–524.
   PubMed Web of Science ®Google Scholar
• Wu HZ, Ong KL, Seeher K, et al. Circulating microRNAs as biomarkers of Alzheimer's disease: a systematic review. J Alzheimers Dis. 2016;49:755–766.
   PubMed Web of Science ®Google Scholar
• Lezak MD. Neuropsychological assessment. New York (NY): Oxford University Press; 1995.
   Google Scholar
• Wechsler D. WMS-IIIUK administration and scoring manual. London, UK: Psychological Corporation; 1998.
   Google Scholar
• Wechsler D. Wechsler memory scale - revised. New York (NY): Psychological Corporation; 1987.
   Google Scholar
• Wechsler D. WAIS-IIIUK administration and scoring manual. London, UK: Psychological Corporation; 1998.
   Google Scholar
• Lezak M. Neuropsychological testing. Oxford, UK: Oxford University Press; 2004.
   Google Scholar
• Kaplan E, Goodglass H, Weintraub S. Boston naming test. Philadelphia, (PA): Lea & Febiger; 1983.
   Google Scholar
• Nelson HE, Willison JR. National adult reading test (NART) test manual (Part II). Windsor, UK: NFER-Nelson; 1991.
   Google Scholar
• van der Elst W, van Boxtel MP, van Breukelen GJ, et al. The Letter Digit Substitution Test: normative data for 1,858 healthy participants aged 24-81 from the Maastricht Aging Study (MAAS): influence of age, education, and sex. J Clin Exp Neuropsychol. 2006;28:998–1009.
   PubMed Web of Science ®Google Scholar
• Ibrahim-Verbaas CA, Bressler J, Debette S, et al. GWAS for executive function and processing speed suggests involvement of the CADM2 gene. Mol Psychiatry. 2016;21:189–197.
   PubMed Web of Science ®Google Scholar
• Bowie CR, Harvey PD. Administration and interpretation of the Trail Making Test. Nat Protoc. 2006;1:2277–2281.
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198.
   PubMed Web of Science ®Google Scholar
• Smith A. Symbol digit modalities test manual - revised. Los Angeles, CA, USA: Western Psychological Services; 1992.
   Google Scholar
• Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270–279.
   PubMed Web of Science ®Google Scholar
• McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263–269.
   PubMed Web of Science ®Google Scholar
• Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–1014.
   PubMed Web of Science ®Google Scholar
• de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119:497–503.
   PubMed Web of Science ®Google Scholar
• McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–1872.
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–184.
   PubMed Web of Science ®Google Scholar
• McGue M, Christensen K. The heritability of level and rate-of-change in cognitive functioning in Danish twins aged 70 years and older. Exp Aging Res. 2002;28:435–451.
   PubMed Web of Science ®Google Scholar
• Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol. 2009;66:1447–1455.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–299.
   PubMed Web of Science ®Google Scholar
• Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;34:2456–2477.
   Google Scholar